Kezar Life Sciences nets $50 mln Series B
South San Francisco-based Kezar Life Sciences, a biopharmaceutical company developing novel small molecule therapeutics, has secured $50 million in Series B funding. Cormorant Asset Management and Morningside Venture led the round with participation from other investors that included Cowen Healthcare Investments, Pappas Ventures, Qiming Venture Partners, Bay City Capital, EcoR1 Capital, Omega Funds and Aju IB Investment.
25 July 2017•1 min read
